DeepMed Research

Shanghai Pharmaceuticals Holding Co.,Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

Early Phase 1

Recruiting

Conditions: NMO Spectrum Disorder

Interventions: Drug: B001 injection
Biological: Placebo

First Posted Date: 2021-12-06

Last Posted Date: 2025-01-27

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 45

Registration Number: NCT05145361

Locations: 🇨🇳
Tangdu hospital,fourth military medical university, Xi'an, Shanxi, China
🇨🇳
Beijing Tiantan Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China

and more 1 locations

Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

First Posted Date: 2021-10-21

Last Posted Date: 2024-05-14

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 231

Registration Number: NCT05088070

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Phase 2

Recruiting

Conditions: Sarcoma, Ewing

Interventions: Biological: TK216+Vincristin

First Posted Date: 2021-09-16

Last Posted Date: 2024-12-20

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 30

Registration Number: NCT05046314

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 5 locations

B002 in Patients With HER2-positive Breast Cancer

Phase 1

Completed

Conditions: Recurrent Breast Cancer
Metastatic Breast Cancer

First Posted Date: 2020-05-11

Last Posted Date: 2023-03-24

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 23

Registration Number: NCT04382352

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

Phase 2

Completed

Conditions: Chronic Abnormal Immune Activation in HIV/AIDS

Interventions: Drug: T8 tablet 0.5mg
Drug: T8 tablet 1mg
Drug: Placebo

First Posted Date: 2019-09-10

Last Posted Date: 2023-03-31

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 151

Registration Number: NCT04084444

Locations: 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
Beijing You An Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Yun Provincial Infectious Disease Hospital, Kunming, Yunnan, China

and more 6 locations

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer

Phase 1

Completed

Conditions: HER2-positive Breast Cancer

First Posted Date: 2019-05-17

Last Posted Date: 2023-09-14

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 30

Registration Number: NCT03953833

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients

Phase 2

Completed

Conditions: Hypertension,Essential

Interventions: Drug: SPH3127 tablet Placebo
Drug: SPH3127 tablet Dose 1
Drug: SPH3127 tablet Dose 2
Drug: SPH3127 tablet Dose 3

First Posted Date: 2018-11-28

Last Posted Date: 2021-11-15

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 120

Registration Number: NCT03756103

Locations: 🇨🇳
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
🇨🇳
Inner Mongolia Medical University Affiliated Hospital, Hohhot, China
🇨🇳
Second People's Hospital of Guangdong Province, Guangdong, China

and more 7 locations

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

Phase 1

Completed

Conditions: CD20 Positive B Cell Non-Hodgkin's Lymphoma

Interventions: Biological: B001

First Posted Date: 2017-11-06

Last Posted Date: 2021-11-15

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 30

Registration Number: NCT03332121

Locations: 🇨🇳
The second affiliated hospital of Guangzhou medical university, Guangzhou, Guangdong, China
🇨🇳
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Placebo matching to SPH3127 50mg
Drug: Placebo matching to SPH3127 100mg
Drug: SPH3127 100mg
Drug: SPH3127 50mg

First Posted Date: 2017-08-21

Last Posted Date: 2021-11-15

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 24

Registration Number: NCT03255993

Locations: 🇨🇳
The capital medical university affiliated Beijing anzhen hospital, Beijing, Beijing, China

The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: SPH3127 200mg Panel B
Drug: SPH3127 200mg Panel A

First Posted Date: 2017-08-15

Last Posted Date: 2021-11-15

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 20

Registration Number: NCT03249753

Locations: 🇨🇳
The capital medical university affiliated Beijing anzhen hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy